Chemotherapy often leaves patients with painful tingling in their hands and feet. This condition is called chemotherapy-induced peripheral neuropathy. It can make daily tasks like buttoning a shirt or holding a cup very difficult. A recent trial looked at whether the drug memantine could help. Seventy-six individuals with this condition took memantine while others took a placebo. The study lasted eight weeks. Both groups felt better, but those taking memantine showed significant improvement in nerve function and pain levels compared to the placebo group. The difference was very strong with a p-value less than 0.001. No serious side effects were reported during the trial. The researchers did not find any safety issues or reasons to stop the medication early. This study offers hope for people struggling with these lingering effects of cancer treatment. However, the results apply only to this specific group and timeframe. More research is needed to confirm these findings for everyone.
Memantine improved neuropathy severity and pain scores versus placebo in CIPN over eight weeksMemantine eased nerve pain and tingling for chemotherapy patients in eight weeks
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider memantine for CIPN; significant symptom improvement vs placebo reported, but safety data not reported.
This randomized clinical trial evaluated memantine versus placebo in 176 individuals with chemotherapy-induced peripheral neuropathy. The intervention involved memantine administration, with placebo serving as the comparator. Follow-up lasted eight weeks. Primary outcomes included neuropathy severity assessed by tuning fork test and neuropathic pain measured by the McGill pain questionnaire. Secondary outcomes included minimal clinically important difference.
Main results showed significant improvement in neuropathy severity in the memantine group compared with placebo (p<0.001). A significant difference between memantine and placebo groups was also observed for neuropathic pain scores (p<0.001). The direction of effect favored memantine for both outcomes.
Safety and tolerability data were not reported. Adverse events, serious adverse events, discontinuations, and overall tolerability were not reported. No limitations were identified in the provided data. Funding or conflicts of interest were not reported. Practice relevance and causality notes were not provided.
The study design supports an association between memantine use and symptom improvement in this specific population. However, the absence of safety reporting limits immediate clinical application. Clinicians should weigh these findings against the lack of safety information before considering memantine for CIPN management.
What this means for you:
Memantine significantly improved nerve pain and function in chemotherapy patients over eight weeks. More on chemotherapy-induced peripheral neuropathy
Memantine reduced PAC burden and new-onset AF in a Phase 2 randomized trial of 241 adults
Common Heart Flutters May Be Linked to Brain Drug
In this Phase 2 randomized, double-blind, placebo-controlled trial of 241 symptomatic adults with frequent PACs (≥1000/24 h), memantine show…
A new study shows a brain medication may calm frequent heart flutters and lower the risk of more serious heart rhythm problems.
Memantine reduces opioid use but not pain in knee osteoarthritis patients after surgery
This Common Memory Drug Cuts Opioid Use After Knee Replacement
A randomized controlled trial in adults with knee osteoarthritis found memantine did not significantly lower pain scores versus placebo, but…
A drug already approved for Alzheimer's disease may help knee replacement patients rely less on opioids during recovery — even if it does no…
Mirtazapine reduces methamphetamine use in phase 3 trial
Mirtazapine cuts meth use days more than placebo in adults with severe addiction
In a phase 3 RCT, mirtazapine 30 mg daily for 12 weeks led to a greater reduction in methamphetamine use days compared to placebo, with a me…
Adults with severe methamphetamine use disorder took less meth when on mirtazapine compared to placebo, with fewer days of use over 12 weeks…
ETVAX shows 48.2% efficacy against moderate-to-severe ETEC diarrhoea in Gambian children despite missing primary endpoint
Early trial shows ETVAX vaccine linked to reduced diarrhoea in Gambian children
This phase 2b randomized controlled trial enrolled 4936 Gambian children aged 6 to 18 months. ETVAX demonstrated 48.2% efficacy against mode…
A phase 2b trial found an ETEC vaccine linked to lower diarrhoea rates in young children, though the main goal was not reached.
View Original Abstract ↓
BACKGROUND AND AIMS: Chemotherapy-induced peripheral neuropathy (CIPN) is a detrimental side effect of chemotherapeutic agents. If left untreated, CIPN can persist for several years following the chemotherapy. CIPN management may enhance the quality of life of the affected patients. This study evaluated the efficacy of memantine, an antagonist of N-methyl-D-aspartate, in CIPN management.
METHODS: This double-blinded randomised clinical trial was performed on 176 individuals with CIPN. Patients were randomised to either the memantine or placebo groups (88 in each). The memantine group received a single daily dose of 5 mg for the initial 3 days. Subsequently, the dosage was increased to 20 mg per day, with 5 mg increments every 3 days. The placebo group received tablets of equal shape and size. All individuals received medications for 8 weeks. The McGill pain questionnaire and tuning fork test were used to evaluate the severity of neuropathic pain in patients, both at baseline and after the intervention ended.
RESULTS: Based on tuning fork test results, significant improvement in neuropathy was observed among patients who received memantine compared with those who received placebo (p<0.001 vs 0.665). McGill pain questionnaire score revealed a significant difference between memantine and placebo groups (p<0.001 for both groups). This difference was also significant after performing intention-to-treat analysis. Moreover, a higher proportion of patients in the memantine group achieved minimal clinically important difference.
CONCLUSION: The use of memantine mitigated the CIPN intensity. Thus, it appears that memantine is a promising option for the management of patients experiencing CIPN.
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
New cancer therapies double response rates for tough lymphoma
Related in Oncology
Sacubitril/Valsartan preserves left ventricular systolic function and attenuates GLS deterioration during chemotherapy
Sacubitril and Valsartan May Protect Heart Function During Chemotherapy
This meta-analysis of randomized controlled trials evaluates sacubitril/valsartan for patients undergoing chemotherapy to manage chemotherap…
A new review suggests the medication sacubitril/valsartan may help preserve heart muscle function for patients undergoing chemotherapy.
DaVinci Single-Port transoral robotic surgery is feasible across multiple indications including oncology and sleep apnea
Single-Port Robot Shows Promise for Sleep Apnea Surgery
This systematic review and meta-analysis of 479 patients evaluates the feasibility of DaVinci Single-Port (SP) transoral robotic surgery (TO…
A new analysis finds single-port robotic surgery for sleep apnea is feasible, with short operating times and low blood loss.
Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancer
Chemoimmunotherapy Shows Higher Response Rates in Bladder Cancer
This network meta-analysis of 2234 patients with muscle-invasive bladder cancer compares neoadjuvant chemoimmunotherapy (NICT), chemotherapy…
A new analysis shows that combining chemotherapy and immunotherapy may lead to higher response rates for patients with muscle-invasive bladd…
MRI Radiomics Predicts TERTp Mutation in Glioma with Moderate Accuracy
MRI Radiomics Help Predict TERTp Mutation in Glioma Patients
Meta-analysis of 14 studies shows MRI radiomics predicts TERTp mutation in glioma with AUC 0.79; combined models improve accuracy to 0.82.
New analysis shows MRI-based radiomics can help predict specific genetic mutations in glioma, potentially aiding early diagnosis and treatme…
From Other Specialties
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.